Evidence map›Paper›PMID 36429088›Full record

ArticleCells2022

JMJD1C Regulates Megakaryopoiesis in In Vitro Models through the Actin Network.

Jialing Wang, Xiaodan Liu, Haixia Wang, Lili Qin, Anhua Feng, Daoxin Qi, Haihua Wang, Yao Zhao, Lihua Kong, Haiying Wang and 3 more

Open access · goldAbstract read
In one paragraph

Article in Cells, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.5field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Article
  3. Choosing the Right Cell Line for Acute Myeloid Leukemia (AML) Research.International journal of molecular sciences · 2023
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 2 institutions in 1 country.

Jialing WangLaboratory for Stem Cell and Regenerative Medicine, the Affiliated Hospital of Weifang Medical University, Weifang 261031, China.
Xiaodan LiuLaboratory for Stem Cell and Regenerative Medicine, the Affiliated Hospital of Weifang Medical University, Weifang 261031, China.
Haixia WangDepartment of Blood Transfusion, the Affiliated Hospital of Weifang Medical University, Weifang 261031, China.
Lili QinDepartment of Hematology, the Affiliated Hospital of Weifang Medical University, Weifang 261031, China.
Anhua FengDepartment of Hematology, the Affiliated Hospital of Weifang Medical University, Weifang 261031, China.
Daoxin QiLaboratory for Stem Cell and Regenerative Medicine, the Affiliated Hospital of Weifang Medical University, Weifang 261031, China.
Haihua WangLaboratory for Stem Cell and Regenerative Medicine, the Affiliated Hospital of Weifang Medical University, Weifang 261031, China.
Yao ZhaoLaboratory for Stem Cell and Regenerative Medicine, the Affiliated Hospital of Weifang Medical University, Weifang 261031, China.
Lihua KongDepartment of Hematology, the Affiliated Hospital of Weifang Medical University, Weifang 261031, China.
Haiying WangDepartment of Hematology, the Affiliated Hospital of Weifang Medical University, Weifang 261031, China.
Lin WangThe School of Physics and Electronic Information, Weifang University, Weifang 261061, China.
Zhenbo HuLaboratory for Stem Cell and Regenerative Medicine, the Affiliated Hospital of Weifang Medical University, Weifang 261031, China.ORCID 0000-0002-6523-7397
Xin XuLaboratory for Stem Cell and Regenerative Medicine, the Affiliated Hospital of Weifang Medical University, Weifang 261031, China.
Weifang Medical University · CNWeifang University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The histone demethylase JMJD1C is associated with human platelet counts. The JMJD1C knockout in zebrafish and mice leads to the ablation of megakaryocyte-erythroid lineage anemia. However, the specific expression, function, and mechanism of JMJD1C in megakaryopoiesis remain unknown. Here, we used cell line models, cord blood cells, and thrombocytopenia samples, to detect the JMJD1C expression. ShRNA of JMJD1C and a specific peptide agonist of JMJD1C, SAH-JZ3, were used to explore the JMJD1C function in the cell line models. The actin ratio in megakaryopoiesis for the JMJDC modulation was also measured. Mass spectrometry was used to identify the JMJD1C-interacting proteins. We first show the JMJD1C expression difference in the PMA-induced cell line models, the thrombopoietin (TPO)-induced megakaryocyte differentiation of the cord blood cells, and also the thrombocytopenia patients, compared to the normal controls. The ShRNA of JMJD1C and SAH-JZ3 showed different effects, which were consistent with the expression of JMJD1C in the cell line models. The effort to find the underlying mechanism of JMJD1C in megakaryopoiesis, led to the discovery that SAH-JZ3 decreases F-actin in K562 cells and increases F-actin in MEG-01 cells. We further performed mass spectrometry to identify the potential JMJD1C-interacting proteins and found that the important Ran GTPase interacts with JMJD1C. To sum up, JMJD1C probably regulates megakaryopoiesis by influencing the actin network.

Indexed as

ActinsThrombocytopeniaHumansJumonji Domain-Containing Histone DemethylasesOxidoreductases, N-DemethylatingRNA, Small InterferingActinsJMJD1C protein, humanJumonji Domain-Containing Histone DemethylasesOxidoreductases, N-DemethylatingRNA, Small InterferingactincytoskeletonJMJD1CmegakaryopoiesisRan GTPase

Identifiers

PMID36429088
PMCPMC9688414
OpenAlexW4309463013

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.